Teledentistry has become an important tool for helping patients access dental expertise when and where they need it. It can ...

Employers that decide to stop covering GLP-1s for weight loss are increasingly pairing that decision with support for the ...

Medication price comparisons remain opaque because multiple price definitions exist and patients typically learn ...

Just two therapies are available to treat MASH. The first was Madrigal Pharmaceuticals’ Rezdiffra (resmetirom), which was ...

Moving the 340B program from upfront discounts to a rebate model would add work for health systems but likely wouldn't change the picture for employers and other plan sponsors, ac ...

Meta-analysis of 13 RCTs (2002–2024; eight countries) found VR reduced pain (SMD −0.76) and anxiety (SMD −1.53), largely ...

Cognitive agency over music choice aligned with lower pain and greater tolerance, paralleling findings in advanced cancer ...

GLP-1 therapies continue to materially influence drug spend, with 2025 overall trend at 8.4% versus 7.9% excluding GLP-1s, ...

OrionRx's Don Anderson, Pharm.D., says a GLP-1 access model built around mandatory wellness coaching resulted in a six-point ...

In stage II–IIIA disease, adjuvant osimertinib reduced mortality risk by 47%, with 74% alive at eight years versus 58% with ...

Yellow eyelid Xanthelasma signals hidden high cholesterol and cardiovascular disease risk, tripling heart attack and stroke ...

Patients with hidradenitis suppurativa show elevated levels of dozens of inflammatory proteins in their blood, and several of ...